Oppenheimer Maintains Outperform on Soleno Therapeutics, Raises Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has maintained an Outperform rating on Soleno Therapeutics and raised the price target from $65 to $73.
October 28, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer has maintained an Outperform rating on Soleno Therapeutics and increased the price target from $65 to $73, indicating positive expectations for the stock.
The increase in price target from $65 to $73 by Oppenheimer suggests a positive outlook for Soleno Therapeutics. The Outperform rating indicates that the analyst expects the stock to perform better than the market average, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100